Pharma: Page 42
-
Q&A
He helped discover BMS’s psoriasis pill Sotyktu. Here’s what he has to say about early science in Big Pharma
Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.
By Michael Gibney • Oct. 17, 2022 -
Opinion
What’s your leadership brand?
Pharma industry leaders share their brand personas.
By Taren Grom • Oct. 14, 2022 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Q&A // First 90 Days
Coming out of stealth, RIGImmune aims to catch up with ever-mutating viruses
President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.
By Kelly Bilodeau • Oct. 13, 2022 -
Robotic pills could open a world of possibilities for the biologics market
As the oral biologic market heats up, Rani Therapeutics is looking to dominate the field with its robotic pill for treatment of chronic conditions.
By Karissa Waddick • Oct. 13, 2022 -
Q&A
Where the CEO of ADC Therapeutics sees ‘huge potential’ in the tech beyond oncology
The “magic bullet” approach of ADCs has been a breakthrough in cancer care — but this excitement could be just the beginning.
By Meagan Parrish • Oct. 12, 2022 -
Podcast
Woman of the Week: HBA’s Nikki Jones
As the Healthcare Businesswomen’s Association’s first chief people and DEI officer, Jones is poised to tackle pay gap inequity, systemic gender bias and leadership barriers impeding women of color.
By Taren Grom • Oct. 12, 2022 -
The digital therapeutics revolution is happening and Big Pharma is buying in — with caution
Companies like Pfizer, Novartis, Sanofi and BMS are diving into the world of digital therapeutics while recognizing the limitations of the young field.
By Michael Gibney • Oct. 10, 2022 -
Sponsored by GoodRx
Beyond buzzwords: Making a practice of diversity, equity and inclusion
Watch Dr. Preeti Parikh, executive medical director at GoodRx, explain how she sees parallels between her mother’s challenges to promote health equity as a physician, and current diversity, equity, and inclusion (DE&I) challenges in the workplace.
Oct. 10, 2022 -
Opinion
Are you a bad boss?
Pharma execs share their tips for being a better leader.
By Taren Grom • Oct. 7, 2022 -
Q&A
Her antibiotic company failed. Now she’s helping others avoid the same fate.
The chief of R&D at CARB-X explains why she believes small antibiotics companies can succeed despite market turmoil.
By Karissa Waddick • Oct. 6, 2022 -
Making Moves
C-suite shake-ups at 23andMe, Moderna signal new stages of growth
With their latest personnel moves, these life sciences companies are preparing for major business shifts.
By Karissa Waddick • Oct. 5, 2022 -
Podcast
Woman of the Week: Janssen’s Fiona Elwood
The neurodegeneration lead at Janssen is driving precision-based medicine to better understand the pathology of neurological disease for the greatest patient impact.
By Taren Grom • Oct. 5, 2022 -
To stay on the leading edge of oncology, AbbVie knows it has to take risks
In a field that has seen rapid progress but ongoing areas of unmet need, AbbVie is betting on emerging tech.
By Kelly Bilodeau • Oct. 4, 2022 -
The 2 areas in life sciences most in need of talent
The industry is feeling the hiring crunch — here’s what pharma companies can do to mitigate the impact.
By Meagan Parrish • Oct. 4, 2022 -
Q&A
It’s electric — speeding up the cell therapy process for scalability
To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.
By Alexandra Pecci • Oct. 4, 2022 -
Q&A
Keytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut
Long-term results showed five-year survival numbers for lung cancer patients that surpassed all others, and Merck's VP of oncology research tells us what he's excited about.
By Michael Gibney • Oct. 3, 2022 -
Sponsored by Avant Healthcare
The evolving roles and responsibilities of digital opinion leaders in medical education
In the past, patients entrusted their healthcare providers to provide information about health-related matters.
Oct. 3, 2022 -
Q&A
That’s not Angry Birds — that’s your doctor learning about novel drugs through gaming
How pharma companies can teach physicians about mechanism of action and other medication lessons with interactive mobile games.
By Alexandra Pecci • Sept. 26, 2022 -
Methadone at home? Emerging tech provides new tool in the fight against opioid addiction
Sonara Health’s inexpensive, specially engineered label and web app allow for at-home, digitally supervised dosing of high-cost or high-risks drugs.
By Alexandra Pecci • Sept. 15, 2022 -
Feds could soon bring COVID-style fight to superbug threat
COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.
By Karissa Waddick • Sept. 13, 2022 -
Sponsored by GoodRx
Medication affordability’s impact on adherence and outcomes
Improved patient affordability is an important lever that can increase adherence, which in turn can improve health outcomes.
Sept. 12, 2022 -
Drug recalls are ticking upwards — here’s how to avoid costly pitfalls
Supply chain challenges, labor shortages and increased FDA inspections are boosting recall risks — but careful planning can keep companies in the clear.
By Kelly Bilodeau • Sept. 8, 2022 -
Pharma’s renewed sickle cell investment lifts a once-shirked disease
Pfizer's $5.4 billion deal to acquire Global Blood Therapeutics invigorated the fast-growing market, and patients are fit to be the benefactors.
By Kelly Bilodeau • Sept. 1, 2022 -
Moderna’s lawsuit against Pfizer and BioNTech explained in 10 quotes
The biotech says that its competitors’ COVID-19 vaccine copied proprietary mRNA technology. Here’s a breakdown of the case.
By Karissa Waddick • Aug. 31, 2022 -
Parexel joins pharmacy giants in quest to boost community health clinical trials
The Community Alliance Network is the latest industry initiative looking to the pharmacy counter to help improve trial recruitment diversity.
By Taren Grom and Karissa Waddick • Aug. 30, 2022